Schwab Charles Investment Management Inc. lifted its stake in shares of Ophthotech Corporation (NASDAQ:OPHT) by 73.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 118,166 shares of the biopharmaceutical company’s stock after buying an additional 49,928 shares during the period. Schwab Charles Investment Management Inc. owned about 0.33% of Ophthotech Corporation worth $433,000 at the end of the most recent quarter.
Several other large investors also recently made changes to their positions in OPHT. Teachers Advisors LLC boosted its position in shares of Ophthotech Corporation by 6.1% during the fourth quarter. Teachers Advisors LLC now owns 52,243 shares of the biopharmaceutical company’s stock valued at $252,000 after buying an additional 2,999 shares during the last quarter. Acadian Asset Management LLC purchased a new position in shares of Ophthotech Corporation during the first quarter valued at approximately $2,157,000. Canada Pension Plan Investment Board boosted its position in shares of Ophthotech Corporation by 397.0% during the first quarter. Canada Pension Plan Investment Board now owns 131,700 shares of the biopharmaceutical company’s stock valued at $482,000 after buying an additional 105,200 shares during the last quarter. Quantitative Investment Management LLC boosted its position in shares of Ophthotech Corporation by 452.0% during the first quarter. Quantitative Investment Management LLC now owns 564,100 shares of the biopharmaceutical company’s stock valued at $2,064,000 after buying an additional 461,900 shares during the last quarter. Finally, Oxford Asset Management boosted its position in shares of Ophthotech Corporation by 827.1% during the first quarter. Oxford Asset Management now owns 364,901 shares of the biopharmaceutical company’s stock valued at $1,336,000 after buying an additional 325,540 shares during the last quarter. 61.56% of the stock is currently owned by institutional investors.
In related news, Chairman David R. Guyer sold 17,678 shares of Ophthotech Corporation stock in a transaction that occurred on Wednesday, July 5th. The shares were sold at an average price of $2.58, for a total value of $45,609.24. Following the completion of the sale, the chairman now owns 37,692 shares in the company, valued at approximately $97,245.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 33,909 shares of company stock valued at $87,485 in the last quarter. 2.00% of the stock is owned by insiders.
Ophthotech Corporation (OPHT) traded down 0.40% on Friday, reaching $2.48. The company’s stock had a trading volume of 160,508 shares. The company’s 50 day moving average price is $2.72 and its 200-day moving average price is $2.88. The stock’s market cap is $89.14 million. Ophthotech Corporation has a 12-month low of $2.24 and a 12-month high of $59.99.
Ophthotech Corporation (NASDAQ:OPHT) last announced its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.07) by $0.45. The firm had revenue of $1.66 million for the quarter, compared to analyst estimates of $1.38 million. During the same quarter in the prior year, the business earned ($0.85) EPS. The firm’s quarterly revenue was down 94.1% on a year-over-year basis. On average, equities analysts expect that Ophthotech Corporation will post $0.29 EPS for the current year.
WARNING: This article was first published by BBNS and is the property of of BBNS. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://baseballnewssource.com/markets/schwab-charles-investment-management-inc-boosts-holdings-in-ophthotech-corporation-opht/1604712.html.
Ophthotech Corporation Profile
Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.
Receive News & Ratings for Ophthotech Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech Corporation and related companies with our FREE daily email newsletter.